Published in Hepatitis Weekly, October 21st, 1996
Comvax is developed by Merck & Co., Inc., West Point, Pennsylvania. It is indicated for vaccination of infants beginning at two months of age against both invasive Haemophilus influenzae type b diseases (Hib), which include meningitis, and hepatitis B virus, an important cause of viral hepatitis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.